Pediatric Atopic Dermatitis: Navigating Patient, Provider, Caregiver Connection with Peter Lio, MD
RAD 2025. Peter Lio, MD, shares details from his presentation on shared decision making when treating children with atopic dermatitis.
Novavax Releases Promising Data from Descriptive Trial for COVID/Flu Combination and Stand-Alone Flu Vaccines
Both investigational vaccines induced strong immunity across all antigens and researchers reported no new safety signals, supporting phase 3 development.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
The US Adult Vaccination Gap: New Analysis Quantifies the Divide, Recommends Solutions
Vaccination rates among US adults are roughly half that of pediatric populations, exposing older adults to risk for disease and complications, according to a new analysis.
Flexible Dosing in in Atopic Dermatitis Treatment: Notes on Real-World Use with Raj Chovatiya, MD, PhD, MSCI
RAD 2025: Chovatiya spoke at RAD about the need to better understand how treatments for AD are being used in the real world, after symptoms subside and skin signs clear.
Understanding Chronic Hand Eczema: More Than Just Atopic Dermatitis
RAD 2025: Jiade Yu, MD, discussed chronic hand eczema as a distinct condition from AD, highlighting its clinical burden and emerging treatments, such as delgocitinib.
Arcutis Begins Study of Roflumilast Cream 0.05% in Infants with Atopic Dermatitis
Arcutis Biotherapeutics announced today the enrollment of the first patient in the phase 2 INTEGUMENT-INFANT trial.
George Medicines Announces FDA Approval of Polypill for Treatment of Hypertension in Adults
The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.
2025 ACOG Annual Clinical & Scientific Meeting: What You May Have Missed
From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.
Clesrovimab Wins FDA Approval for Prevention of RSV LRTD in Infants During First RSV Season
The preventive monoclonal antibody is designed to protect infants against RSV infection through 5 months and is administered at the same dose, regardless of weight.
Q&A: Cumulative Life Course Impairment of Atopic Dermatitis with Mona Shahriari, MD
RAD 2025: As expert dermatologist Shahriari explains it, eczema may be just another rash on your schedule but for a patient, it could be the reason they don't leave the house.
Chronic Hand Eczema: Clinical Insights and Future Directions from RAD 2025
RAD 2025: Explore expert insights on chronic hand eczema, its differences from atopic dermatitis, and emerging treatments in this informative video series.
Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study
RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.
Q&A: Managing Chronic Itch With Renowned Investigator Gil Yosipovitch, MD
RAD 2025: World expert on the pathophysiology of itch Gil Yosipovitch, MD, answers questions on the disease of chronic itch and on the expanding options for targeted treatment.
Beyond the Rash: Collaborative Insights on Pediatric Atopic Dermatitis
RAD 2025: Lisa Swanson, MD, shares insights on pediatric atopic dermatitis, addressing questions from both a dermatologist's and an allergist's perspective.
Persistent Underutilization of Systemic Therapy for Atopic Dermatitis Highlights Gap Between Need and Care
RAD 2025: Mobile health data reveal a troubling decline in systemic treatment for moderate-to-severe atopic dermatitis, underscoring issues in access and clinical inertia.
Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color
Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.
Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years
RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.
Mona Shahriari, MD: Explore the Psychosocial Burden of Atopic Dermatitis with Your Patients—Ask Questions
RAD 2025: Mona Shahriari, MD, underscored the cumulative life impact of atopic dermatitis, reminding clinicians that there is always far more to the condition than meets the clinical eye.
Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis
RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.